Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus neoadjuvant chemoradiotherapy in stromal-activated esophageal adenocarcinoma
NL-OMON54869Phase 2Suspended
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Amsterdam University Medical Center. Started Jan 2021; status: suspended.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON54869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54869.